MINE (chemotherapy)


MINE in the context of chemotherapy is an acronym for one of the chemotherapy regimens used for treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
Today this regimen is often combined with monoclonal antibody rituximab. In this case the regimen is called R-MINE or MINE-R.
The -MINE regimen consists of:
  1. 'ituximab - anti-CD20 monoclonal antibody that can kill both normal CD20-expressing B cells and malignant ones;
  2. 'esna to prevent the development of hemorrhagic cystitis which may otherwise result from ifosfamide administration;
  3. 'fosfamide - an alkylating antineoplastic agent from oxazafosforine group;
  4. 'ovantrone - a synthetic antracycline analogue that is able to intercalate DNA and thus prevent cell division ;
  5. toposide - a topoisomerase inhibitor.

    Dosing regimen